205 related articles for article (PubMed ID: 36333526)
1. Ex vivo expansion of natural killer cells for hematological cancer immunotherapy: a systematic review and meta-analysis.
Çubukçu HC; Mesutoğlu PY; Seval GC; Beksaç M
Clin Exp Med; 2023 Oct; 23(6):2503-2533. PubMed ID: 36333526
[TBL] [Abstract][Full Text] [Related]
2. Artificial feeder cells expressing ligands for killer cell immunoglobulin-like receptors and CD94/NKG2A for expansion of functional primary natural killer cells with tolerance to self.
Michen S; Frosch J; Füssel M; Schackert G; Momburg F; Temme A
Cytotherapy; 2020 Jul; 22(7):354-368. PubMed ID: 32451262
[TBL] [Abstract][Full Text] [Related]
3. Ex Vivo Expansion of Human NK Cells Using K562 Engineered to Express Membrane Bound IL21.
Somanchi SS; Lee DA
Methods Mol Biol; 2016; 1441():175-93. PubMed ID: 27177666
[TBL] [Abstract][Full Text] [Related]
4. Ex vivo expansion of natural killer cells using cryopreserved irradiated feeder cells.
Baek HJ; Kim JS; Yoon M; Lee JJ; Shin MG; Ryang DW; Kook H; Kim SK; Cho D
Anticancer Res; 2013 May; 33(5):2011-9. PubMed ID: 23645750
[TBL] [Abstract][Full Text] [Related]
5. Expansion, purification, and functional assessment of human peripheral blood NK cells.
Somanchi SS; Senyukov VV; Denman CJ; Lee DA
J Vis Exp; 2011 Feb; (48):. PubMed ID: 21339714
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of serum-free media formulations in feeder cell-stimulated expansion of natural killer cells.
Moseman JE; Foltz JA; Sorathia K; Heipertz EL; Lee DA
Cytotherapy; 2020 Jun; 22(6):322-328. PubMed ID: 32278551
[TBL] [Abstract][Full Text] [Related]
7. An Uncoupling of Canonical Phenotypic Markers and Functional Potency of
Lieberman NAP; DeGolier K; Haberthur K; Chinn H; Moyes KW; Bouchlaka MN; Walker KL; Capitini CM; Crane CA
Front Immunol; 2018; 9():150. PubMed ID: 29456538
[TBL] [Abstract][Full Text] [Related]
8. Genetically re-engineered K562 cells significantly expand and functionally activate cord blood natural killer cells: Potential for adoptive cellular immunotherapy.
Ayello J; Hochberg J; Flower A; Chu Y; Baxi LV; Quish W; van de Ven C; Cairo MS
Exp Hematol; 2017 Feb; 46():38-47. PubMed ID: 27765614
[TBL] [Abstract][Full Text] [Related]
9. High log-scale expansion of functional human natural killer cells from umbilical cord blood CD34-positive cells for adoptive cancer immunotherapy.
Spanholtz J; Tordoir M; Eissens D; Preijers F; van der Meer A; Joosten I; Schaap N; de Witte TM; Dolstra H
PLoS One; 2010 Feb; 5(2):e9221. PubMed ID: 20169160
[TBL] [Abstract][Full Text] [Related]
10. Optimization of Human NK Cell Manufacturing: Fully Automated Separation, Improved Ex Vivo Expansion Using IL-21 with Autologous Feeder Cells, and Generation of Anti-CD123-CAR-Expressing Effector Cells.
Klöß S; Oberschmidt O; Morgan M; Dahlke J; Arseniev L; Huppert V; Granzin M; Gardlowski T; Matthies N; Soltenborn S; Schambach A; Koehl U
Hum Gene Ther; 2017 Oct; 28(10):897-913. PubMed ID: 28810809
[TBL] [Abstract][Full Text] [Related]
11. Expanded clinical-grade membrane-bound IL-21/4-1BBL NK cell products exhibit activity against acute myeloid leukemia in vivo.
Zhao XY; Jiang Q; Jiang H; Hu LJ; Zhao T; Yu XX; Huang XJ
Eur J Immunol; 2020 Sep; 50(9):1374-1385. PubMed ID: 32357256
[TBL] [Abstract][Full Text] [Related]
12. Feeder Cells at the Interface of Natural Killer Cell Activation, Expansion and Gene Editing.
Gurney M; Kundu S; Pandey S; O'Dwyer M
Front Immunol; 2022; 13():802906. PubMed ID: 35222382
[TBL] [Abstract][Full Text] [Related]
13. Expansion of NK Cells Using Genetically Engineered K562 Feeder Cells.
Phan MT; Lee SH; Kim SK; Cho D
Methods Mol Biol; 2016; 1441():167-74. PubMed ID: 27177665
[TBL] [Abstract][Full Text] [Related]
14. Natural Killer Cell Expansion with Autologous Feeder Layer and Anti-CD3 Antibody for Immune Cell Therapy of Hepatocellular Carcinoma.
Hosseinzadeh F; Ai J; Ebrahimi-Barough S; Seyhoun I; Hajifathali A; Muhammadnejad S; Hosseinzadeh F; Shadnoush M; Dabiri Oskouei F; Verdi J
Asian Pac J Cancer Prev; 2019 Dec; 20(12):3797-3803. PubMed ID: 31870124
[TBL] [Abstract][Full Text] [Related]
15. Expansion of Human NK Cells Using K562 Cells Expressing OX40 Ligand and Short Exposure to IL-21.
Kweon S; Phan MT; Chun S; Yu H; Kim J; Kim S; Lee J; Ali AK; Lee SH; Kim SK; Doh J; Cho D
Front Immunol; 2019; 10():879. PubMed ID: 31105701
[No Abstract] [Full Text] [Related]
16. Genetic Engineering and Enrichment of Human NK Cells for CAR-Enhanced Immunotherapy of Hematological Malignancies.
Soldierer M; Bister A; Haist C; Thivakaran A; Cengiz SC; Sendker S; Bartels N; Thomitzek A; Smorra D; Hejazi M; Uhrberg M; Scheckenbach K; Monzel C; Wiek C; Reinhardt D; Niktoreh N; Hanenberg H
Front Immunol; 2022; 13():847008. PubMed ID: 35464442
[TBL] [Abstract][Full Text] [Related]
17. Clinical-grade, large-scale, feeder-free expansion of highly active human natural killer cells for adoptive immunotherapy using an automated bioreactor.
Sutlu T; Stellan B; Gilljam M; Quezada HC; Nahi H; Gahrton G; Alici E
Cytotherapy; 2010 Dec; 12(8):1044-55. PubMed ID: 20795758
[TBL] [Abstract][Full Text] [Related]
18. A New Ex Vivo Method for Effective Expansion and Activation of Human Natural Killer Cells for Anti-Tumor Immunotherapy.
Yang H; Tang R; Li J; Liu Y; Ye L; Shao D; Jin M; Huang Q; Shi J
Cell Biochem Biophys; 2015 Dec; 73(3):723-9. PubMed ID: 27259316
[TBL] [Abstract][Full Text] [Related]
19. Natural killer cell adoptive immunotherapy: Coming of age.
Baggio L; Laureano ÁM; Silla LMDR; Lee DA
Clin Immunol; 2017 Apr; 177():3-11. PubMed ID: 26883680
[TBL] [Abstract][Full Text] [Related]
20. Natural killer cells: a promising immunotherapy for cancer.
Chu J; Gao F; Yan M; Zhao S; Yan Z; Shi B; Liu Y
J Transl Med; 2022 May; 20(1):240. PubMed ID: 35606854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
